The decision by the Food and Drug Administration to withhold approval for a therapy utilizing MDMA, also known as ecstasy and molly, in treating post-traumatic stress disorder has left many advocates disappointed. Taylor West, the executive director of the Healing Advocacy Fund, a nonprofit dedicated to promoting safe psychedelic therapy, expressed concern over the FDA’s stance.
West believes that the path to making these groundbreaking therapies accessible to those in need may now shift to the state level. The federal bureaucracy, according to West, is ill-equipped to evaluate the unique combination of medicine and therapy that psychedelic treatments entail.
MORE: Most pregnant women do not drink enough water, study finds
Research conducted by Lykos Therapeutics on MDMA-assisted psychotherapy offered hope to millions of Americans suffering from PTSD. Traditional treatments for PTSD often fall short, relying on medications like Paxil and Zoloft in combination with cognitive behavioral and exposure therapies. However, a clinical trial conducted by Lykos showed promising results, with a significant number of participants finding relief and even achieving complete remission through MDMA-assisted therapy.
Despite these positive outcomes, an independent advisory panel advised against FDA approval of MDMA in therapy due to concerns surrounding safety, diversity in the study group, and research integrity. The FDA’s subsequent decision to deny approval has left advocates exploring alternative paths for legalization and regulation.
The Multidisciplinary Association for Psychedelic Studies, in collaboration with Lykos, urged the FDA to reconsider its decision and vowed to address the concerns raised. However, with federal approval now uncertain, the focus may shift towards state-level initiatives to advance the use of psychedelics in mental health treatment.
One of the challenges faced by Lykos is that federal regulators are accustomed to assessing medications independently, rather than as part of a holistic treatment approach that includes therapy. Despite setbacks at the federal level, West believes that progress can still be made through state-level programs that demonstrate the effectiveness of these innovative therapies.
In addition to MDMA studies, researchers have also been exploring the therapeutic potential of psilocybin, found in certain mushrooms known for their hallucinogenic effects. Studies suggest that psilocybin may be beneficial in treating various mental health conditions, including substance use disorders, depression, and anxiety. Several states, including Oregon and Colorado, have already approved programs to offer psychedelic-assisted therapy under supervision at licensed facilities.
Although psilocybin remains classified as a Schedule I substance by the DEA, states like Oregon and Colorado have successfully integrated it into mental health treatment protocols without federal interference. The growing body of research supporting the efficacy of these therapies provides hope for advocates like West, who believe in expanding access to these innovative treatments.